Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yann-Alexandre Vano

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Bulletin Du Cancer|March 11, 2023
[Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies]Zoé Guillaume, Yves Allory, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2016
Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University HospitalsCamille Tlemsani, Olivier Mir, Dimitri Psimaras, et al.
BJU International|April 4, 2017
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancerAlice Clément-Zhao, Marie Auvray, Hail Aboudagga, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 14, 2025
Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinomaIvan Pourmir, Nadine Benhamouda, Thi Tran, et al.
Cancers|November 13, 2021
First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, et al.
NPJ Precision Oncology|May 9, 2025
Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinomaXiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, et al.
Journal for Immunotherapy of Cancer|January 23, 2025
Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinomaXiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2019
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinomaMarie Auvray, Edouard Auclin, Philippe Barthelemy, et al.
Clinical Genitourinary Cancer|February 21, 2017
Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell CarcinomaEdouard Auclin, Camille Bourillon, Eleonora De Maio, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2019
Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40]Marie Auvray, Edouard Auclin, Philippe Barthelemy, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Bulletin Du Cancer|March 11, 2023
[Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies]Zoé Guillaume, Yves Allory, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2016
Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University HospitalsCamille Tlemsani, Olivier Mir, Dimitri Psimaras, et al.
BJU International|April 4, 2017
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancerAlice Clément-Zhao, Marie Auvray, Hail Aboudagga, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 14, 2025
Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinomaIvan Pourmir, Nadine Benhamouda, Thi Tran, et al.
Cancers|November 13, 2021
First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, et al.
NPJ Precision Oncology|May 9, 2025
Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinomaXiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, et al.
Journal for Immunotherapy of Cancer|January 23, 2025
Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinomaXiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2019
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinomaMarie Auvray, Edouard Auclin, Philippe Barthelemy, et al.
Clinical Genitourinary Cancer|February 21, 2017
Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell CarcinomaEdouard Auclin, Camille Bourillon, Eleonora De Maio, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2019
Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40]Marie Auvray, Edouard Auclin, Philippe Barthelemy, et al.
Pageof 5